Your fact-checks will appear here
The risks associated with the RSV vaccine, including the risk of Guillain–Barré syndrome.
authorized for the 2025–2026 season are recommended for people 6 months and older under shared clinical decision-making and are designed to match current circulating strains, with regulators and manuf...
The 2025–2026 COVID-19 vaccines—formulated to match recent Omicron-lineage viruses—continue to show meaningful protection, especially against hospitalization and death, and public-health agencies endo...